How do you manage treatment in a breast cancer patient with low clinical risk disease with a high risk Mammaprint?  

The MINDACT trial demonstrated no survival difference in patients with low clinical risk disease who received chemotherapy versus who did not.

Would you give chemotherapy in this setting if oncotype showed elevated RS of 52?